Urovant Sciences, Inc
5281 California Ave, Suite #100
Tel: +1 949 226 6029
About Urovant Sciences, Inc
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant's lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit www.urovant.com.
Stock Symbol: UROV
Stock Exchange: NASDAQ
75 articles with Urovant Sciences, Inc
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting
Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation
Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological treatment for benign prostatic hyperplasia (BPH).
Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo
Vibegron met both co-primary endpoints and all seven key secondary endpoints
The company announced positive topline results from its Phase III EMPOWUR trial of viregron in patients with overactive bladder.
Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
Urovant Sciences announced it will host a conference call and live webcast to discuss topline results from the EMPOWUR international pivotal phase 3 study on Tuesday, March 19, 2019 at 8:30 a.m. ET.
Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
Urovant Sciences announced it has entered into a debt financing agreement with Hercules Capital, Inc. for up to $100 million.
Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended December 31, 2018.
Urovant Sciences Ltd. announced it will report 2018 third fiscal quarter financial results after the close of U.S. financial markets on Wednesday, February 13, 2019.
The event will feature presentations by clinical experts in the field of urology, Dr. Roger R. Dmochowski, Vanderbilt University, and Dr. Steven Kaplan, Icahn School of Medicine at Mount Sinai.
Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with abdominal pain due to irritable bowel syndrome (IBS) on December 31, 2018.
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced chief executive officer Keith A. Katkin is scheduled to present a corporate overview at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:00 a.m. PT in San Francisco.
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to participate in the Piper Jaffray Healthcare Conference on Tuesday, November 27
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
Urovant Sciences Ltd. today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target
The study demonstrated once-daily vibegron was well-tolerated and improved OAB symptoms
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.